Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A 12-week study to evaluate the 24 hour pulmonary function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) once daily compared with Salmeterol/Fluticasone Propionate (FP) Inhalation Powder twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD)
fluticasone furoate/vilanterol
HZC113107
NCT01342913
Pulmonary Disease, Chronic Obstructive
Phase 3
 
September 2013

Powered by ideaPoint, Inc.